Phase 2 N=451 Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for Episodic Treatment of Cold Sores
Recurrent Herpes Labialis
Primary: Clinician Assessed Duration of the Classical Herpetic Lesion — 162.7; 163.6 hours
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=173 Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores
Recurrent Herpes Labialis
Primary: Clinician Assessed Duration of Complete Healing of the Herpetic Episode — 129.6; 154.6 hours
Phase 2 N=30 Mirabegron and Physiological Function in Cold Environments
Resting Energy Expenditure · Thermogenesis · Brown Adipose Tissue
Primary: Cumulative Resting Energy Expenditure — 456.4; 494.7; 481.3; 492.8 kcal
Phase 2 N=17 MIrabegron and Physiological Function in Cold Environments
Resting Energy Expenditure · Thermogenesis · Brown Adipose Tissue
Primary: Cold Temperature Deflection Point — 22.8; 22.97 degrees Celsius
N/A N=22 Cold Milk for Dysphagia in Preterm Infants
Dysphagia of Newborn
Primary: Percentage of Infants With Improvement of Dysphagia — 58 Percentage of patients
N/A N=56 Effect of Cold Therapy Implementation on Multi-modal Postoperative Pain Management
Pain, Postoperative
Primary: Post-operative Pain Score — 4; 4.5 units on a scale
Phase 3 N=24 A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)
Cold Agglutinin Disease
Primary: Number of Patients Achieving a Response (R) at Week 24 — 8; 2 Participants
Phase 3 N=24 A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)
Agglutinin Disease, Cold
Primary: Part A: Percentage of Participants With Response to Treatment — 54.2 percentage of participants
Phase 3 N=7 Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan
Cold Agglutinin Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 7; 1 Participants
Phase 3 N=42 A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion
Cold Agglutinin Disease
Primary: Part A: Percentage of Participants With Response to Treatment — 72.7; 15.0 percentage of participants — p=<0.001
Phase 2 N=24 Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
Warm Autoimmune Hemolytic Anemia · Cold Agglutinin Disease
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity — 5; 5; 7; 6 Participants
N/A N=26 Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic
Asthma
Primary: Airway Symptom Scores Experienced by Subjects During the 1st 4 Days of the Infection — 8.72; 2.77 units on a scale — p=0.049
N/A N=93 The Effect of Vibration and Cold on Pain and Anxiety Associated With Chest Tube Removal Following CABG
Pain, Procedural · Pain, Postoperative · Coronary Artery Bypass Surgery
Primary: Mediastinal Chest Tube Pain — 1.38; 1.76; 1.43; 0.21 score on a scale
Phase 2 N=31 Cold Urticaria Treatment With Xolair
Cold Contact Urticaria
Primary: Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo — -10.6; -10.4; -0.3 degree celcius — p=0.001
N/A N=116 Electric Warming Mattress to Prevent IPH During LSCS
Hypothermia · Anesthesia · Obstetric Anesthesia Problems
Primary: This Study Intends to Investigate Whether an Electric Warming Mattress Can Reduce Post-operative Hypothermia (Defined as Body Temperature of Less Than 36.0ºC) in…